All In Biotech

Drug Trial Radar · NCT07810062

A Phase II Trial to Assess Extended Safety and Tolerability of Subcutaneous CAP256V2LS and VRC07-523LS in HIV- Negative Women

A Double-blinded, Randomized, Placebo-controlled Phase II Trial to Assess Extended Safety and Tolerability of Subcutaneous CAP256V2LS and VRC07-523LS in HIV Negative Women

Last checked: Nov 19, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 990 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

990

Actual

Start

Aug 28, 2023

Primary completion

Jun 30, 2024

Study completion Jun 30, 2025

Sponsor

Lead sponsor
Centre for Infectious Disease Research in ZambiaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
European and Developing Countries Clinical Trials Partnership (EDCTP); Medical Research Council, South Africa; University of Cape Town; Amsterdam Institute for Global Health and Development; Centre for the AIDS Programme of Research in South Africa; National Institute of Communicable Diseases - NICD
First posted
Sep 9, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Single group
Masking
Single (participant)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 30 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A double blinded, Randomized, Placebo- controlled phase II trial to assess extended safety and tolerability of subcutaneous CAP256V2LS and VRC07-523LS in HIV- negative women

Conditions

  • To Assess Extended Safety and Tolerability of Subcutaneous CAP256V2LS and VRC07-523LS Monoclonal Antibodies in HIV-negative Women

Interventions

  • Broad band monoclonal antibodies named as CAP256V2LS and VRC07- 523LSBiological

    HIV prevention

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants with any grade 3 or higher reactogenicity events within the first 3 days and adverse events after administration of CAP256V2LS in combination with VRC07-523LSTime frame: 18 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Matero Clinical Research Site

    Lusaka, Lusaka Province, Zambia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.